The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Safety and Efficacy Clinical Study of SNS-595 in Patients With Advanced Small Cell Lung Cancer
Official Title: Phase 2 Open-Label, Multicenter Clinical Study of the Safety and Efficacy of Intravenous Administration of SNS-595 in Patients With Advanced Small Cell Lung Cancer (SCLC)
Study ID: NCT00298896
Brief Summary: The purpose of this study is to evaluate the objective tumor response rate to SNS-595 in patients with small cell lung cancer (SCLC).
Detailed Description: Other objectives of this study are to assess the safety, survival rate, best response, time to disease progression, duration of tumor response, and to explore several potential biomarkers to see how these levels change after administration of SNS-595.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
University of California Davis, Sacramento, California, United States
Stanford University Medical Center, Stanford, California, United States
Rush University Medical Center, Chicago, Illinois, United States
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Duke University Medical Center, Durham, North Carolina, United States
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Sarah Cannon Research Institute, Nashville, Tennessee, United States
The Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Cross Cancer Institute, Edmonton, Alberta, Canada
BC Cancer Agency, Vancouver, British Columbia, Canada
Juravinski Cancer Centre, Hamilton, Ontario, Canada
Hopital Charles LeMoyne, Greenfield Park, Quebec, Canada
Hopital Laval, Sainte-Foy, Quebec, Canada
Name: Craig Berman, MD
Affiliation: Sunesis Pharmaceuticals
Role: STUDY_DIRECTOR